Intravenous administration of amphotericin B entrapped in liposomes: induction of high serum levels of TNF alpha.
The rate of objective response to second-line chemotherapy with cyclophosphamide, adriamycin and vincristine increased from 13% to 55% in two consecutive series of patients with small-cell lung cancer when the therapy was potentiated by amphotericin B (2 mg/kg i.v.) entrapped in liposomes (= ampholiposomes). Patients who received ampholiposomes had a rapid and significant (p less than 0.01) increase of serum TNF alpha concentrations (median value: from less than 10 to 261 pg/mL) followed by a rise in serum neopterin and CRP. No major side effects were observed. Administration of ampholiposomes appeared to be a safe method for obtaining relatively high serum levels of TNF alpha that could potentiate anticancer chemotherapy.
Sculier
J P
JP
Service de Médecine, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium.
Body
J J
JJ
D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000378:metabolism; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004337:Drug Carriers; D004357:Drug Synergism; D006801:Humans; D008081:Liposomes; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D019798:Neopterin; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D014750:Vincristine / Q000008:administration & dosage
D004337:Drug Carriers; D008081:Liposomes; D014409:Tumor Necrosis Factor-alpha; D001708:Biopterins; D014750:Vincristine; D019798:Neopterin; D000666:Amphotericin B; D004317:Doxorubicin; D003520:Cyclophosphamide; D002097:C-Reactive Protein